On December 5, 2022, the Federal Court of Appeal (FCA) upheld the validity of changes to the list of countries used for international reference pricing by the Patented Medicine Prices Review Board (PMPRB). This new schedule of countries, known as the PMPRB11, removes the United States and Switzerland while adding six lower-price jurisdictions.[i] The
Latest Post
More Posts
Legal update: common interest privilege in commercial transactions
Federal government creates new Ombudsperson to oversee corporate activity abroad
Legal update: the Reducing Regulatory Costs for Business Act
Investment Canada Act update: new thresholds and national security in the news
New forfeiture of corporate property regime in Ontario
The InterOil decision: robust and independent fairness opinion required
Can a cause of action be assigned in a corporate transaction?
Solicitor-client privilege in mergers and acquisitions
Changes of note to the Yukon Business Corporations Act
Subscribe: Subscribe via RSS
Firm/Org